Sell Diamicron mr tab 60mg 60pcs best price

One modified release tablet contains gliclazide 60 mg. Excipient with known effect: lactose monohydrate. Action Pharmacology: Pharmacodynamics: Mechanism of action: Gliclazide is a hypoglycemic sulfonylurea oral antidiabetic active substance differing from other related compounds by an N-containing heterocyclic ring with an endocyclic bond. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. Increase in postprandial insulin and C-peptide secretion persists after two years of treatment. In addition to these metabolic properties, gliclazide has hemovascular properties. Pharmacodynamic effects: Effects on insulin release: In type 2 diabetics, gliclazide restores the first peak of insulin secretion in response to glucose and increases the second phase of insulin secretion. A significant increase in insulin response is seen in response to stimulation induced by a meal or glucose. Hemovascular properties: Gliclazide decreases microthrombosis by two mechanisms which may be involved in complications of diabetes: A partial inhibition of platelet aggregation and adhesion, with a decrease in the markers of platelet activation (beta thromboglobulin, thromboxane B2). An action on the vascular endothelium fibrinolytic activity with an increase in tPA activity. Pharmacokinetics: Absorption: Plasma levels increase progressively during the first 6 hours, reaching a plateau which is maintained from the sixth to the twelfth hour after administration. Intra-individual variability is low. Gliclazide is completely absorbed. Food intake does not affect the rate or degree of absorption. Distribution: Plasma protein binding is approximately 95%. The volume of distribution is around 30 liters. A single daily intake of GLICLAZIDE (DIAMICRON MR) 60 mg maintains effective gliclazide plasma concentrations over 24 hours.